Elitek-rasburicase: an effective means to prevent and treat @entity5052 associated with XXXX , a Meeting Report, Dallas, Texas, January 2002.

@entity1 @entity5405 @entity706 @entity5 @entity3624 @entity11792 @entity13579 @entity1778 @entity56 @entity5052 @entity208 @entity414
Renal precipitation of @entity414 associated with @entity5405 ( @entity5405 ) is a major complication in the management of @entity1778 , @entity706 , and other @entity5 . Management of hyperuricema has historically consisted of administration of @entity208 , hydration, alkalinization to maintain pH between 7.0 and 7.3, and in some cases diuresis. @entity208 , a @entity3624 analogue, blocks @entity3624 oxidase and formation of @entity414 . Urate oxidase converts @entity414 to @entity13579 , which is 5-10 times more soluble than @entity414 . @entity1 cannot express urate oxidase because of a nonsense mutation. Urate oxidase was initially purified from @entity11792 fungus. Treatment with this nonrecombinant product had been effective in preventing renal precipitation of @entity414 in @entity5 @entity1 , but was associated with a relatively high frequency of @entity56 . This enzyme was recently cloned from A. flavus and is now manufactured as a recombinant protein. Clinical trials have shown this drug to be more effective than @entity208 for prevention and treatment of @entity5052 in @entity1778 and @entity706 @entity1 . This drug has been approved in Europe as well as the US and several clinical trials are in progress to further determine its clinical utility in other @entity1 subsets. The purpose of this meeting was to discuss usefulness of recombinant urate oxidase, also known as rasburicase, Fasturtec, and Elitek, for the management of @entity5405 in certain @entity5 @entity1 .
